Table 4.
Outcomes
| Ticagrelor+Eptifibatide Bolus (n=35) Group 1 | Ticagrelor+Eptifibatide Bolus and Infusion (n=35) Group 2 | P Value | |
|---|---|---|---|
| In‐hospital events | |||
|
Periprocedural myonecrosis, n (%) (>5×99th percentiles or >20% increase in troponin levels) |
9 (26) | 7 (20) | 0.57 |
| Baseline hemoglobin, g/dL | 13.62±1.54 | 13.35±1.8 | 0.84 |
| Postprocedure hemoglobin, g/dL | 13.04±1.55 | 12.38±1.80a | 0.22 |
| Bleeding (academic Research Consortium 3b) | 0 | 1 | |
| Follow‐up events | |||
| Duration of follow‐up, month | 10±4.4 | 11±3.7 | |
| Death | 0 | 1 | |
| Stroke | 0 | 0 | |
| TLR | 1 | ||
| NSTEMI | 1 | ||
| Major adverse cardiovascular events, n | 1 | 2 | |
a
P<0.05 compared with baseline hemoglobin. NSTEMI indicates non‐ST‐elevation myocardial infarction; TLR, target lesion revascularization.